AVERY Dennison has announced the launch of AD Procerta, described as a lab and testing facility service that will ‘transform’ how the pharmaceutical industry navigates the ‘often complex world’ of label material testing.
The firm explained that there are ‘many variables’ involved when creating labels for pharmaceutical products, such as medications, which need to be applied ‘perfectly’ for patient safety. There is a need to understand legal and regulatory requirements and how labels will perform in specific environments.
Avery Dennison said its new service will help pharmaceutical packaging engineers and brand owners ‘simplify and streamline’ the process.
“We identified a market need,” said Benoît Jourde, senior manager new growth platforms Europe, Avery Dennison. “It is a market need that is not really fulfilled at the moment. Although there are some excellent third-party laboratories out there, they are either missing the expertise specifically on self-adhesive labels, or they have extremely long lead times.”
Avery Dennison said the new solution ‘speeds up the process, provides fact-based information, and offers facilities that can accommodate specific testing methods’.
Leiden Bio Science Park in the Netherlands is home to AD Procerta’s laboratory, which provides access to a range of testing capabilities.
“A variety of label-specific tests can be performed at the facility with the guidance of an expert team to determine whether a label material is suitable for a given application,” said Jos van Noort, principal scientist global pharma innovations, Avery Dennison.
The business revealed that a ‘few’ big pharmaceutical companies have piloted the service over the last two years, with the goal of launching it this year.
